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ABSTRACT
Hepatitis B virus (HBV) is one of the greatest killers of human 
beings.  The production of recombinant HBV vaccine via genetic 
engineering and mass immunization of the world population with 
the vaccine have had huge success in bringing down the number of 
infected people.  However, until now there is no effective treatment 
for HBV infections.  Nucleoside analogues are commonly used 
to treat chronic hepatitis B patients, but prolonged treatments 
have resulted in the selection of drug resistant strains and vaccine 
escape mutants. More importantly, HBV is linking arms with the 
human immunodeficiency virus (HIV) to kill more humans.  Many 
dedicated scientists and highly motivated doctors have risked their 
lives to control the spread of HBV and search for a cure for this 
deadly virus.  Their ultimate goal is to eradicate the virus from this 
planet and make the world a better place for everyone.  Therefore, 
the main aim of this talk is to provide a comprehensive review 
of their contributions in the development of vaccines, diagnostic 
assays, therapeutics and drug delivery systems to fight HBV.  
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INTRODUCTION
Hepatitis B virus (HBV) has taken countless lives throughout human 
history.  It has infected about one third of the world’s population, 
of which 370 million are chronic carriers and about one million 
people continue to die each year (Michel & Tiollais, 2010).  HBV 
causes liver cirrhosis, liver cancer (hepatocellular carcinoma) and 
other liver complications in humans.  The virus poses a serious 
health problem worldwide, particularly in South East Asia, China 
and Africa (Figure 1), with at least 8% of the population being 
chronically infected.  It is highly contagious.  Shockingly, it is 200 
times more infectious than the human immunodeficiency virus 
(HIV) and up till now it has killed more people than HIV.  The virus 
is transmitted via blood or body fluids, including blood transfusion, 
contaminated needles and syringes, sexual contact and perinatal 
transmission from mother to baby during childbirth.  
Figure 1  Geographic distribution of chronic HBV infection.
Hepatitis B surface antigen (HBsAg) is a marker of chronic HBV 
infection. More than 7% of the population in Africa, China and South 
East Asia are chronically infected with HBV. (Source, CDC. Travellers’ 
Health, Yellow Book. http,//wwwn.cdc.gov/travel/yellowbookch4-
HepB.aspx).
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 HBV belongs to the family of Hepadnaviridae and the genus 
of Orthohepadnavirus.  It only infects humans and other higher 
primates, such as, chimpanzees and orangutans.  The viral infectious 
particle (also known as virion) was named after David S. Dane 
who first reported observation of the particle under a transmission 
electron microscope (Dane et al., 1970).  The virion found in the 
blood of chronically infected patients is spherical in shape with 
a diameter of about 42 nm (Figure 2).  It is enveloped by a lipid 
bilayer derived from the liver cell membranes.  Embedded in the 
lipid bilayer are three distinct but related forms of surface antigens 
(HBsAg), namely S- (small), M- (middle) and L- (large) HBsAg. 
The viral capsid located inside the envelope is made of many copies 
of the core antigen (HBcAg).  Within the capsid is a partially 
double-stranded DNA genome of about 3.2 kb which associates 
with the polymerase protein (P) harbouring reverse transcriptase 
and DNA-dependent DNA polymerase activities (Tan & Ho, 2014). 
Figure 2  A schematic representation of the virion structure of HBV. 
HBV envelope contains three forms of surface antigen (HBsAg), 
namely, S- (small), M- (middle) and L- (large) HBsAg.  The viral 
capsid located inside the envelope is made of many copies of the core 
antigen (HBcAg). The representations of the L, M and S forms of 
HBsAg have no quantitative or positional significance.  
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 Many scientists have risked their lives to study this deadly virus. 
Uncountable numbers of doctors have put their lives in danger to 
treat and save patients infected by this virus.  The ultimate goal of 
these unsung heroes is to eradicate the virus from this planet and 
make the world a better place.  Therefore, the main aim of this talk 
is to provide a comprehensive review on the contributions of these 
heroes, particularly, my mentor, students and collaborators, on their 
endless efforts to combat HBV.  This lecture is divided into four 
sections based on the main strategies that have been used widely to 
control and combat HBV: (1) Vaccination, (2) Diagnosis, (3) Drug 
discovery, and (4) Drug and gene delivery.
VACCINE DEVELOPMENT
Hepatitis B surface antigens (HBsAg) were discovered by Baruch 
Blumberg in the blood of an Australian aborigine in the 1960s 
(Blumberg, 1964).  He was awarded the Nobel Prize in Medicine 
in 1976. Under an electron microscope, three morphologically 
distinct particles are commonly observed in the sera of chronic 
carriers: 42 nm infectious particles which appear as spheres and 
another two types of non-infectious particles which look like 
spheres or filaments with a diameter of 22 nm (Dane et al., 1970). 
The filamentous particles appear in different lengths.  The non-
infectious particles are enormously abundant in the blood stream of 
chronic carriers, about 1,000- to 100,000-fold in excess compared 
to the virion (Chai et al., 2008).  The biological function of these 
non-infectious particles is unclear but they are thought to serve as 
decoys that trap anti-HBV antibodies and thus weaken the efficacy 
of the human’s immune response. The non-infectious particles 
are mainly composed of HBsAg and host-derived lipids, but they 
do not contain the nucleocapsid and the viral genetic materials. 
Baruch Blumberg and Irving Millman purified these non-infectious 
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particles from infected sera and applied them as a subunit vaccine 
against HBV infection (Blumberg, 2013). This vaccine was patented 
by Fox Chase Cancer Center, and approved by the Food and Drug 
Administration (FDA), USA (Blumberg, 2013).  The vaccine was 
marketed by Merck & Co., Inc. in 1981, under the trade name, 
Heptavax B.  Although this vaccine was highly protective against 
the viral infection, large amounts of infected sera are needed which 
could be contaminated by other infectious pathogens present in the 
sera.  This vaccine was therefore discontinued in 1990 and replaced 
by a safer recombinant DNA vaccine (Muraskin, 1995).
Recombinant DNA Technology Reinvents Hepatitis B 
Vaccine 
In 1969, there was a serious outbreak of HBV at the Royal 
Infirmary of Edinburgh which killed patients and staff in the kidney 
transplant unit.  Kenneth Murray (known as Ken to his friends), a 
molecular biologist at the University of Edinburgh and also a co-
founder of Biogen Inc. employed recombinant DNA technology 
to clone the viral DNA in a bacterial plasmid and to produce the 
viral proteins in bacteria (Burrell et al., 1979, Pasek et al.,1979). 
The experiment was a success and the first patent on recombinant 
DNA molecules capable of expressing HBcAg and HBsAg was 
filed in December 1978 (Hofschneider & Murray, 2001).  Ken 
and his colleagues continued to produce the viral proteins in yeast 
by using recombinant DNA technology, and in the early 1980s 
the S-HBsAg was successfully produced in yeast (Valenzuela et 
al., 1982, Hitzeman et al., 1983, Miyanohara et al., 1983) and 
was demonstrated to protect chimpanzees from HBV challenges 
(McAleer et al., 1984, Murray et al., 1984).  This recombinant 
vaccine is safer compared to the subunit vaccine purified from the 
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sera of infected patients as the latter may be contaminated with other 
infectious pathogens.  Production of this recombinant vaccine is also 
less laborious and less time-consuming compared with the plasma-
derived subunit vaccine.  For commercialization, the owner of the 
patent, Biogen Inc., licensed the patent to SmithKline Beecham. 
The subsequent recombinant vaccine, Engerix-B®, was approved 
by the Food and Drug Administration (FDA) in the late 1980s 
(Frost & Reich, 2009).  This vaccine, manufactured and marketed 
by SmithKline Beecham, is currently the best-selling recombinant 
hepatitis B vaccine worldwide, with sales amounting to more than 
US$ 1 billion per year.  Following mass immunization of newborn 
babies with the recombinant vaccine since the 1990s, the rates 
of HBV carriers and liver cancer cases dropped significantly in 
many countries (Chen, 2009, 2010).  The invention of recombinant 
hepatitis B vaccine has undoubtedly changed the vaccine industries 
and made this planet a safer place for mankind.  In addition, 
the production of the hepatitis B vaccine via recombinant DNA 
technology has now become a model for many other recombinant 
vaccines against human and animal pathogens.  The first inventor of 
the recombinant hepatitis B vaccine, Ken, used the royalties from 
the hepatitis B vaccine to support a great many charitable activities, 
postgraduate and undergraduate scholarships, library facilities, 
research grants, laboratories, conferences, science programmes for 
schoolchildren, lecture rooms and halls as well as building projects. 
Ken left not only a rich legacy but good personal values for many 
generations to learn.    
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Why there is a Continuing Need for New Hepatitis B 
Vaccines?
The reinvention of the HBV vaccine with recombinant DNA 
technology is a success story in human history and the vaccine has 
indeed saved countless lives worldwide.   Does this mean that the 
human being is fully protected by the yeast derived recombinant 
vaccine?  Why is there always a need to improve, invent and 
formulate new HBV vaccines?  The main reason is that the virus is 
competing with human beings to survive on this planet.  Could we 
totally eradicate the virus from this planet?  This is a huge challenge 
and of course it is the ultimate goal of human beings.  HBV has 
been mutating and immune-escape mutants with amino acid 
replacements, deletions and insertions across the immunodominant 
region or the ‘a’ determinant of HBsAg have been reported widely 
(Zanetti et al., 1988, Coleman, 2006, Zuckerman & Zuckerman, 
2003).  Vaccine-escape mutants with nucleotide changes in their 
polymerase (pol) and S genes were found in chronic hepatitis B 
patients treated with nucleoside analogue drugs (Lapiński et al., 
2012).  Most frightening is that HBV and HIV co-infect millions 
of people worldwide, particularly in sub-Saharan Africa and East 
Asia (van den Berg et al., 2009).  The patients co-infected by these 
two viruses have a higher rate of liver-related mortality compared 
to those infected only by HIV-1 or HBV alone (Thio et al., 2002). 
Furthermore, only 20-70% of patients infected by HIV produced 
anti-HBsAg antibodies after a standard HBV vaccination compared 
to 90-95% in healthy adult individuals (Laurence, 2005).  All 
the above medical and scientific evidence, as well as the genetic 
diversity of HBV, strongly justify the continuing need for the 
development of new HBV vaccines.
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Recombinant HBsAg Vaccines 
The nucleotide sequence of the viral DNA has been determined 
(Pasek et al., 1979) and its translated products have been studied in 
detail with the invention of nucleotide sequencing methods in the 
1970s.   The envelope proteins, S-, M- and L-HBsAg are translated 
from one single open reading frame (ORF) by using three different 
in-frame start codons and a common stop codon (Figure 3).  Thus, 
they have a large sequence in common at their C-termini.  The 
largest of them, the L-HBsAg (39 kDa), contains the PreS1 region of 
108 or 119 residues (depending on serotype) followed by the PreS2 
amino acids of 55 residues and the S region which comprises 226 
residues.  The second largest protein, the M-HBsAg (31 kDa), has 
the PreS2 and S regions. The smallest of these proteins, S-HBsAg 
(24 kDa), contains only the S region.  All these proteins are either 
glycosylated or un-glycosylated at Asn-146 of the S region.  The 
M-HBsAg has an additional glycosylation site at Asn-4 of the 
PreS2 region.  A myristyl group is linked to the glycine residue at 
the N-terminus of L-HBsAg (Persing et al., 1987).
Figure 3   Envelope proteins of HBV. 
The translation products of the HBsAg gene are shown as lines of 
different thickness.  S-, M- and L-HBsAg are translated from a 
common open reading frame of the HBsAg gene by the use of three 
in-frame initiation codons (*) at the 5’-ends of the PreS1, PreS2 and S 
coding regions.  Glycosylation is indicated by G. MYR represents the 
myristic acid. 
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 The S-HBsAg can self-assemble with host lipids to form 
spherical virus-like particles (VLPs) with a diameter of about 22 nm. 
It has been produced in many eukaryotic systems via recombinant 
DNA technology, including Saccharomyces cerevisiae, Pichia 
pastoris, BHK-21 cells, CHO cells, Sf9 insect cells and tomato 
plants.  Currently, the recombinant DNA vaccines are based on the 
VLPs of S-HBsAg produced in yeast cells.  These vaccines are safer 
compared to the non-infectious particles purified from the sera of 
infected patients.  Although the recombinant vaccines are highly 
effective, about 5-10% of healthy people show no or low immune 
responses after vaccination with three doses of these vaccines 
(Ottone et al., 2007).  As the PreS regions of the L-HBsAg contain 
several epitopes, incorporation of these regions in current HBsAg 
vaccines may help improve the protective level in slow- or non-
responders.  A straight forward experiment to prove this concept is to 
produce the L-HBsAg in yeast cells and study its efficacy.  Cloning 
of the L-HBsAg in Pichia pastoris was performed by Fazia (2010) 
who demonstrated that the purified product assembled into spherical 
particles closely resembling those isolated from human serum. 
Interestingly, apart from the L-HBsAg,  the VLPs also contained 
the M-, and S-HBsAg.  These particles are reactive against human 
anti-HBsAg, implying their potential as an immunogen (Yong & 
Tan, 2015).  
Multi-component Vaccines Based on the Hepatitis B 
Virus Capsid
Inside the viral envelope is a capsid which serves as a protective 
container for the viral genome.  The capsid is assembled from 
many copies of core proteins, commonly known as core antigens 
(HBcAg).  The full-length core protein contains 183 amino acids 
with a molecular mass of approximately 22 kDa.  The first 144 
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amino acids of the HBcAg are required for self-assembly and 
the C-terminal region (residues 145-183) is highly basic, rich in 
arginine residues, and is believed to interact with the pregenomic 
RNA (Pasek et al, 1979).  Advancement of molecular biology from 
the 1980s to 1990s facilitated the expression of HBcAg in E. coli 
(Pasek et al., 1979,  Burrell et al., 1979, Edman et al., 1981, Stahl 
et al., 1982), tissue culture cell lines (Gough and Murray, 1982, 
Rossinck et al., 1986), yeast (Kniskern et al., 1986), baculovirus 
(Hilditch et al., 1990), Acetobacter methanolicus (Schroder et al., 
1991), Xenopus oocytes (Zhou and Standring, 1991) and plants 
(Huang et al., 2006, Mechtcheriakova et al., 2006).  Interestingly, 
in these different hosts, HBcAg self-assembled into capsids 
morphologically similar to authentic nucleocapsids isolated from 
infected livers (Cohen and Richmond).  Among these organisms, 
E. coli is the most successful expression system for the production 
of HBcAg in scientific research and commercial applications.  In 
general, one litre of E. coli culture grown in a shake flask produces 
about 5 mg of HBcAg (Tan et al., 2003).  As the C-terminal end 
of the HBcAg is highly rich in arginine residues and about half of 
them are encoded by codon AGA, supplementation of the level of 
AGA tRNA in E. coli cells by a plasmid encoding the T4 AGA 
tRNA gene  doubled the yield of HBcAg (Tan et al., 2003).  The 
optimal conditions for the production of HBcAg in a shake flask and 
a stirred tank bioreactor were studied intensively by Tey et al. (2004, 
2006).  Extensive mutation analysis of the HBcAg indicates that 
the N-terminal end of 140 residues is sufficient for self- assembly 
(Zlotnick et al., 1996) and the yield of truncated HBcAg (tHBcAg) 
derivatives lacking the arginine rich region is about 5- to 10-times 
higher than that of the full-length HBcAg (Tan et al., 2003). Of 
course this has significantly reduced the cost of HBcAg production 
for downstream applications, particularly diagnosis.  Due to its high 
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commercial value, several methods have been established for the 
release of HBcAg from E. coli cells and these include enzymatic 
reactions, ultrasonication (Ho et al., 2006), bead milling (Ho et 
al., 2008a, 2008b) and high pressure homogenization (Ho et al., 
2008c).  In addition, many methods have been established to purify 
the HBcAg produced in E. coli, which include sucrose gradient 
ultracentrifugation (Tan et al., 1999), gel filtration chromatography 
(Tang et al., 2007), expended bed chromatography (Ng et al., 2007, 
2008, Yap et al. 2010), aqueous two-phase systems (Tou et al., 
2014), agarose gel electrophoresis (Yoon et al., 2013) and negative 
chromatography (Lee et al., 2015, 2016).
 HBcAg expressed in E. coli assembles into two sizes of 
particles: small and large, approximately 30 and 34 nm in diameter, 
respectively (Crowther et al., 1994).  The large particle, which 
constitutes about 85% of the total population, corresponds to a 
triangulation number T=4 arrangement of 240 HBcAg subunits. 
The remaining population is the smaller sized particle, which 
corresponds to a T=3 shell of 180 HBcAg monomers.  The factors 
which control the distribution of these two types of particles are not 
as yet understood.  Furthermore, the physiological implications of 
these two different species of capsids in the assembly of the HBV 
virion in the human liver still remain an enigma. An interesting 
feature of the capsids is that they have holes penetrating the protein 
shell and it is thought that small molecules enter the capsid through 
these holes during the reverse transcription of pregenomic RNA to 
a double-stranded DNA (Crowther et al., 1994).
	 HBcAg	consists	of	4	α-helices	(Figure	4)	(Böttcher	et al., 1997, 
Wynne	et al.,	1999).		During	the	capsid	assembly,	two	molecules	
of	HBcAg	interact	together	to	form	a	dimer,	which	serves	as	an	
intermediate	to	assemble	into	the	large	and	small	particles.		Apart	
from	hydrophobic	forces,	Cys-61	from	both	monomers	forms	a
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Figure 4  HBV	capsid	assembly. 
(a)	Polypeptide	fold	of	the	hepatitis	B	core	antigen	(HBcAg)	monomer.	
Each	monomer	consists	of	4	a-helices	(indicated	as	cylinders).		
The	two	longest	a-helices	are	~42	Å	long and	joined	by	a	loop	
corresponding	to	amino	acids	78-82.		The	first	long	helix	is	roughly	
straight,	whereas	the	second	long	helix	has	a	kink	in	the	middle.		
The	numbers	indicate	approximate	amino	acid	positions	in	HBcAg.	
Amino-	and	carboxyl-ends	are	indicated	by	N-	and	C-,	respectively.	
(b)	Two	HBcAg	monomers	interact	to	form	a	dimer	which	acts	as	an	
intermediate	to	assemble	into	(c)	capsid	containing	either	180	or	240	
monomers.	(Source,	Tan	et al., 2007).
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disulfide	bridge	and	stabilizes	the	dimer	and	eventually	the	whole	
capsid.	 	The	four	longest	α-helices	of	the	dimer	(two	from	each	
monomer,	Figure	4)	form	a	protruding	spike	on	the	shell.		Hence,	
the	shell	surface	is	spiky	with	120	and	90	spikes,	for	the	large	and	
small	particles,	 respectively.	 	The	 immunodominant	 loop	of	 the	
HBcAg	(amino	acids	74-89)	is	located	close	to	the	tip	of	the	spikes.	
  Over the past three decades, HBV capsids have been studied 
extensively as a molecular carrier for foreign epitopes in the 
development of multi-component vaccines and diagnostic reagents. 
Hundreds of HBcAg fusion proteins containing insertions of 
foreign sequences, either at the N- or C-terminus, or the major 
immunodominant region located near the tip of the capsid spikes 
(Figure 5a), have been produced in E. coli, and they too assemble 
into particles, demonstrating the potential of HBcAg as a molecular 
carrier in multi-component vaccine development.  
 The crystal structure of the HBV capsid (Wynne et al., 1999, 
Tan et al., 2007) revealed that the N-terminus of the HBcAg is 
located on the outside of the capsid.  This feature suggests that the 
heterologous sequence fused to the N-terminus of the monomer 
can be displayed on the surface of the capsid.  The first attempt 
for N-terminal insertion was reported by Stahl et al. (1982), by 
replacing the first two residues of HBcAg with the eight residues 
of β-galactosidase and a linker sequence of three amino acids. 
This N-terminal fusion peptide was later proven to be exposed on 
the exterior of the capsid using X-ray diffraction analysis (Tan et 
al., 2007).  An additional His-tag fused to the β-galactosidase and 
the tripeptide linker (Yap et al., 2009) was also demonstrated to be 
located outside the shell by cryoelectron microscopy and image 
reconstruction (Figures 5b & 5c) (McGonigle et al., 2015).   
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Figure 5  Display of foreign epitopes on HBV capsid. 
(a) Foreign polypeptides can be fused to the N- or C-terminus, or 
the major immunodominant region (residues 78-82) of the hepatitis 
B core antigen (HBcAg).  His-tag fused to the N-terminal end of 
HBcAg protrudes from the surface of T=3 (b) and T=4 (c) HBV 
capsids (Courtesy of Dr. David Bhella, University of Glasgow).  BLV 
(bovine leukemia virus), FeLV (feline leukemia virus), FMDV (foot-
and-mouth disease virus), HBsAg (hepatitis B virus surface antigens), 
HCV (hepatitis C virus), HEV (hepatitis E virus), HIV-1 (human 
immunodeficiency virus type 1), HPV (human papillomavirus), 
HRV-2 (human rhino virus type 2), PV1 (poliovirus type 1), SIV 
(simian immunodeficiency virus), NiV (Nipah virus),  SIV (simian 
immunodeficiency virus).
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 Several studies showed that foreign sequences fused to the 
N-terminal ends may impair the formation of capsids unless a 
flexible linker is incorporated immediately preceding the N-terminus 
of HBcAg (Clarke et al., 1987, Yap et al., 2009).  Foreign epitopes 
linked to the N-terminus of HBcAg include those from the foot-and-
mouth disease virus (FMDV; Beesley et al., 1990), feline leukemia 
virus (FeLV; Clarke et al., 1990), human rhino virus type 2 (HRV-2; 
Brown et al., 1991), poliovirus type 1 (PV1; Clarke et al., 1990), 
simian immunodeficiency virus (SIV; Yon et al., 1992), Bordetella 
pertussis (Charles et al., 1991), hepatitis B virus surface antigens 
(HBsAg; Schödel et al., 1992), human immunodeficiency virus 
type 1 (HIV-1; Isaguliants et al., 1996), human influenza A virus 
(Neirynck et al., 1999), Hanta virus (Koletzki et al., 2000) and the 
Nipah virus (Yap et al., 2011).  These derivatives assembled into 
highly immunogenic capsid-like particles.  One of these chimeric 
particles carrying  the external domain of human influenza A matrix 
2 (M2) protein conferred 100% protection against flu challenge 
in mice (Neirynck et al., 1999) and has successfully completed a 
phase I clinical trial (De Filette et al., 2008). 
 X-ray crystallography and cryoelectron microscopic analyses 
revealed that the C-terminal end of HBcAg is located inside the 
capsid (Conway et al., 1997, Wynne et al., 1999, Watts et al., 2002), 
thus insertion of a foreign epitope to this end is most likely to be 
hidden inside the capsid and as a result has a lower immunogenicity. 
Many studies have shown that the arginine rich region at the 
C-terminal end can be replaced by foreign sequences of varying 
length, up to 720 amino acids (Yoshikawa et al., 1993), without 
impairing particle formation.  A series of foreign epitopes (Figure 
5a) from HBsAg (Stahl and Murray, 1989), HIV-1 (von Brunn et 
al., 1993), bovine leukemia virus (BLV; Ulrich et al., 1992), human 
cytomegalovirus (HCMV; Tarar et al., 1996), Hanta virus (Ulrich 
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et al., 1998), HEV (Touze et al., 1999), FMDV (Nekrasova et al., 
1997) and HCV (Yoshikawa et al., 1993), have been fused to the 
C-terminal end of HBcAg.  All these chimeric particles assembled 
into particles.  Some of these foreign epitopes, which are believed to 
be located inside the assembled particles, can be detected by specific 
antibodies.  It is believed that the inserted foreign epitopes emerge 
through or are located near the edge of the capsid holes, and thus 
become accessible to antibodies (Crowther et al., 1994, Kenney et 
al., 1995). Another possibility is that these chimeric particles are 
less stable, disrupted in the preparation and reaction conditions 
used and thus exposed to antibodies.  
 Another attractive position for displaying foreign sequences is 
the immunodominant region of HBcAg (residues 78-82) located 
at the tip of the capsid spike (Figure 5a).  This position appears to 
have the capacity to accommodate longer heterologous sequences 
and has been shown to induce  strong B cell and T cell immune 
responses.  For instance, the whole molecule of green fluorescent 
protein (GFP) of 238 amino acids was successfully displayed on the 
HBcAg particles and fluoresced (Kratz et al., 1999).  The chimeric 
particle also elicited a strong humoral response against the native 
GFP.  In addition, a range of fusion proteins at the immunodominant 
region has also been reported.  These fusion proteins harbour the 
epitopes from human rhinovirus type 2 (HRV2; Brown et al., 1991), 
simian immunodeficiency virus (SIV; Yon et al., 1992), FMDV 
(Chambers et al., 1996), human papillomavirus (HPV; Tindle et 
al., 1994), HBsAg (Schödel et al., 1990), Hanta virus (Ulrich et 
al., 1998) and the Nipah virus (Yap et al., 2012).
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Hepatitis B Vaccine Based on Phage Particles
Apart from the HBV capsid, phage particles provide an alternative 
means to display immunogens.  Tan et al. (2005) fused the highly 
conformational immunodominant region of HBsAg (residues 
111–156), or denoted as ‘a’ determinant, to the C-terminal end of 
the 10B capsid protein of the T7 phage (Figure 6).  The recombinant 
phage, namely T7–HBsAg111–156, displayed 415 copies of the 
foreign epitope on one particle and about 1016 copies of reasonably 
pure ‘a’ determinant can be produced and purified from a 1-litre 
culture within 6 hours.  Rabbits immunized with the recombinant 
phage mounted an immune response which was as good as that of 
a human-derived HBsAg, demonstrating the potential of the T7–
HBsAg111–156 phage particle as a vaccine candidate.  
 The filamentous phage, M13 (Figure 7), has been widely used 
to display HBV immunogenic epitopes.  The M13 phage contains 
about 2700 copies of the pVIII coat protein which allows a very 
high copy number to be displayed on the surface of the viral particle. 
A 12-residue epitope, HBsAg28-39, was fused successfully to the 
pVIII coat protein and the recombinant phage particles were used 
to immunize BALB/c (H-2d) mice in the absence of an adjuvant. 
After 8 days of immunization, an MHC class I restricted HBsAg 
specific cytotoxic T lymphocytes (CTL) response was observed, 
demonstrating the potential of the recombinant M13 phage particles 
as potent immunogens without an adjuvant.   For a low copy number 
display, in general 3 to 5 copies, foreign epitopes are fused to the 
pIII protein located at the tip of the filamentous phage.  The PreS 
regions (163 residues) of L-HBsAg were fused to the pIII protein 
but the expression level of the fusion protein was very low (Kok et 
al., 2002).  This could be due to the low copy number of the pIII 
protein.  Nevertheless, the fusion protein, PreS-g3P, was shown 
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to be highly antigenic (Kok et al., 2002). In addition, the HBcAg 
(about 180 residues) fused to the pIII protein was shown to be highly 
immunogenic in BALB/c mice (Bahadir et al., 2011).
Figure 6 Display of the immunodominant region of HBV on 
bacteriophage T7.
Purple circles represent residues 111–156 of small hepatitis B surface 
antigens (S-HBsAg) fused to the C-terminal end of the 10B capsid 
protein of T7 phage and displayed on the surface of the phage particle. 
The phage can display 415 copies of foreign peptides up to 50 residues.
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Figure 7  A schematic representative of bacteriophage M13.
The virion contains a ssDNA surrounded by approximately 2700 
copies of the major coat protein (pVIII). The minor coat proteins (pIII, 
pVI, pVII & pIX) with 3 to 5 copies are located at either end. Fusion 
of foreign oligonucleotides into the genes encoding the coat proteins 
results in the corresponding peptides  being displayed on the surface of 
the phage particle.
VACCINE DEVELOPMENT
Past,  ➣ HBV vaccines save millions of lives.
 ➣ Recombinant DNA technology reinvents HBV 
vaccines.
Present,  ➣ Virus-like particles are potential carriers for 
multicomponent vaccines.
Future,  ➣ Co-display of HBV and HIV functional epitopes on 
a single virus-like particle.
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DIAGNOSIS OF HEPATITIS B MARKERS
Having infected about one-third of the world’s population, HBV’s 
impact on the global economy has always been the driving 
force for the development of streamlined diagnostic assays. The 
determination of HBV infections is mainly through detection of the 
presence of viral nucleic acids, antigens, as well as the antibodies 
produced against these antigens by the human body. The appearance 
of these serological and genetic markers during acute, chronic and 
occult infections is summarized in Figure 8.
 For detection of HBV infection, the clinically used serological 
markers include both viral antigens and host antibodies produced 
against these viral antigens. These include HBsAg, HBeAg, anti-
HBsAg, anti-HBeAg and anti-HBcAg. About 90-95% of healthy 
adults infected by HBV will mount an effective immune response 
against the virus, thereby terminating the infection. For acute 
infections, the first detectable marker is the HBsAg, followed by 
the HBeAg. At around 3 months post-infection, anti-HBcAg can be 
detected in the serum samples of patients infected by HBV. Anti-
HBsAg and anti-HBeAg can be detected after 7 months. Overall, 
acute infections can be determined via detection of HBsAg during 
infection, and anti-HBcAg after about 6 – 7 months, where the HBV 
is resolved (Figure 8). Upon virus clearance, anti-HBsAg and anti-
HBcAg remain present and provide protection to the individuals 
against re-infection by HBV.
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Figure 8   HBV markers in sera during acute, chronic and occult 
infections.
The period in months is indicated below the boxes containing the 
markers.  The presence of the markers indicated in boxes with broken 
lines varies in individuals. Occult infection is characterized by the 
presence of HBV DNA but in the absence of HBsAg.
 However, not everyone is  fortunate enough to have undergone 
an acute infection. Approximately 5 – 10% of healthy adults, 50% of 
young children and 90% of infants fail to respond efficiently against 
HBV infection, which results in persisting infection or known as 
chronic infection. For chronic infection, both the HBsAg and anti-
HBcAg persist after 6 – 7 months post-infection, and can last a 
whole life-time. Thus to determine if the infection is chronic, a test 
to detect the presence of HBsAg 6 – 7 months post-infection has 
to be carried out. The HBeAg and anti-HBeAg titers, on the other 
hand, are to measure the level of viral infectivity and seroconversion 
status (Hatzakis et al., 2006).
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 The third type of infection, known as occult infection, is 
characterized by the presence of viral DNA but in the absence of 
detectable HBsAg (Said, 2011). Unlike acute and chronic infections 
with the presence of antigens or antibodies, detection of occult HBV 
infection often requires sensitive PCR assay targeting the viral DNA. 
Apart from detecting occult infection, the quantity of viral DNA is 
also used to monitor HBV replication, disease progression, as well 
as to investigate the host’s responses to drug treatments (Hatzakis 
et al., 2006).
 To detect the serological markers mentioned above, a highly 
sensitive and specific radioimmunoassay (RIA) was developed in 
the early 1970s. RIA involves the use of a solid phase as a platform 
for antigen-antibody interaction, in which one of the antibodies is 
labelled with radioisotope. It has been used for the detection of 
HBsAg and anti-HBsAg (Lander et al., 1971, Ling and Overby, 
1972, Purcell et al., 1973).  However, the use of radioisotopes 
requires special precautions, licensing and equipment.  Thus, it 
was quickly replaced by the enzyme-linked immunosorbent assay 
(ELISA), which utilizes enzyme-substrate reactions instead of 
radioisotopes. Since then, ELISA has been used widely for detecting 
HBV serological markers such as the HBsAg (Wolters et al., 
1976), HBcAg (Bredehorst et al., 1985), HBeAg (van der Waart 
et al., 1978, von der Waart et al., 1978), anti-HBcAg (Gerlich and 
Luer, 1979) and anti-HBeAg (Korec et al., 1990). A more recent 
method which utilizes quantitative real-time PCR (qPCR) is able 
to monitor the replication of HBV DNA and quantify its amount 
at different stages of the viral infection (Jardi et al., 2001).  In the 
advancement of these methods, we believe that phage display can 
be used to generate antibodies and diagnostic reagents.  Therefore, 
the main aim of our study was to detect hepatitis B markers with 
phage display technology.
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Phage Displayed Peptides as Diagnostic Reagents
Diagnostic assays, particularly ELISA, involve molecular 
interactions between the antigen and antibody. More precisely, the 
paratope of an antibody interacts with an epitope or a mimotope 
(discontinuous epitope) on the surface of an antigen. These 
paratopes and epitopes can be formed from less than 10 amino 
acid residues. Therefore, random short peptide sequences which 
interact strongly with these epitopes or paratopes can be selected 
from a random phage displayed peptide library. 
 Phage display technology is a powerful tool that can be used to 
rapidly select novel peptides which bind to a wide range of antigens, 
ranging from macromolecules, for instance proteins, lipids, and 
carbohydrates, to whole cells such as parasites, bacteria and viruses. 
Through recombinant DNA technology, any peptide can be fused 
to the major or the minor coat proteins of bacteriophages and be 
displayed on the surface of the bacteriophages (Smith and Petrenko, 
1997). The vast peptide libraries displayed on bacteriophages can 
then be prepared and screened for specific ligands which bind 
to targeted protein via a process known as biopanning (Scott 
and Smith, 1990).  Biopanning is illustrated in Figure 9, where 
an immobilized target protein is exposed to the phage displayed 
peptide library. Recombinant phages displaying peptides that 
interact with the target protein will remain attached, while others 
are removed during washing. The bound phages can then be eluted 
and propagated in E. coli. The propagated phages can then be used 
for another round of screening to select only specific ligands which 
interact strongly with the target protein. The nucleotide sequences 
of the selected clones are then determined to deduce the amino acid 
sequences of the ligands.
 Through biopanning against recombinant HBV capsid, a 
paratope mimic displayed on the M13 phage was isolated from a 
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disulfide constrained random heptapeptide library (Ho et al., 2003). 
This paratope with the sequence WSFFSNI was used as a diagnostic 
reagent for detecting HBcAg released from the virion in HBV 
positive serum samples (Hasmoni et al., 2005). Phage-ELISA, dot 
blot assay and immunoprecipitation assay were developed based 
on this paratope mimic (Hasmoni et al., 2005). In a phage-ELISA 
and dot blot assay, the recombinant phage binds HBcAg with a 
K
D
 of 2.5 nM, and was able to detect a minimum amount of 10 ng 
HBcAg.
Figure 9  Processes in biopanning of a phage displayed peptide library 
against a target protein. 
Purified HBsAg is coated on a microtiter plate well. A phage displayed 
peptide library is added and phages are allowed to interact with 
HBsAg. Unbound phages are washed off. Bound phages are eluted 
and propagated in E. coli.  The selection process is repeated for 3 
to 4 cycles and the identity of the selected phages is determined by 
sequencing the gpIII gene carrying the insert.
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 Tan et al. (2005) isolated a phage-displayed cyclic peptide, 
bearing the sequence ETGAKPH, that interacts strongly with 
the immunodominant region of HBsAg through biopanning. 
The paratope mimic, ETGAKPH, was selected from a disulfide 
constrained random heptapeptide library displayed on the pIII of 
phage M13 (5 copies per phage) by panning against human plasma-
purified HBsAg.  The recombinant phage harbouring ETGAKPH 
binds strongly to HBsAg with a K
D
 of 2.9 nM.  Hence, the whole 
phage was used as a diagnostic reagent to establish both direct and 
indirect phage-ELISA for detection of HBsAg in HBV infected 
patients, as shown in Figure 10.  Both direct and indirect phage-
ELISA were able to detect HBsAg down to 1 pg/ml.  
Figure 10   Phage-ELISA for detecting hepatitis B virus surface 
antigen (HBsAg).
(A) The major steps used in an assay for detecting HBsAg immobilized 
on a solid support using a phage carrying the HBsAg-binding 
peptide. (B) The major steps used in an assay for detecting HBsAg 
by immobilizing a phage carrying HBsAg-binding peptide on a solid 
support. Anti-M13 or anti-HBsAg antibodies conjugated to an enzyme 
is added to interact with the bound phage or HBsAg, then substrates for 
the enzyme are added to produce a measurable signal. 
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  Most recently, Muhamad et al. (2013) determined the three-
dimensional structure of ETGAKPH with nuclear magnetic 
resonance (NMR) and demonstrated its interaction with the ‘a’ 
determinant of HBsAg. Collectively, these data justify the use of 
phage-displayed peptides as a sensitive diagnostic reagent, instead 
of the conventional use of antibodies. The sensitivity of the phage-
based diagnostic assay was further enhanced by Monjezi et al. 
(2013) by incorporating qPCR to phage-ELISA, as shown in Figure 
11. Amazingly, the resultant phage display mediated immuno-PCR 
(PD-IPCR) is 10,000 times more sensitive than the phage-ELISA 
(Monjezi et al., 2013).
 Compared to the conventional ELISA which uses viral antigens 
or antibodies against these antigens, the isolation of phage born 
peptides is cheaper, faster and easier as immunization of animals 
is not required. The overall affinity of a selected peptide towards 
an antigen or antibody can be further improved by displaying 
the peptide at high copy number on the major coat protein of a 
bacteriophage, such as the pVIII in the filamentous phage, or 10B 
of phage T7.  Phage born peptides have also been employed vastly 
as diagnostic reagents for the Newcastle disease virus (Lee et al., 
2006, Ramanujam et al., 2004), Nipah virus (Eshaghi et al., 2005), 
cucumber mosaic virus (Gough et al., 1999), Salmonella enterica 
serovar Typhi (Tang et al., 2003, Thong et al., 2007) and HIV-1 
(Palacios-Rodriguez et al., 2007), all of which demonstrate the 
potential of phage displayed peptides as highly sensitive diagnostic 
reagents for the detection of etiological reagents.  The phage-based 
diagnostic assays that can be developed are not limited to ELISA, 
but also other diagnostic technology such as flow cytometry, 
proximity ligation assay and lateral flow strip assays.  
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Figure 11  Phage display mediated TaqMan real-time immuno-PCR. 
HBV positive human serum sample is heated to release the HBcAg 
from the virion (1).  The HBcAg is immobilized on a microtiter 
plate well (2) and interacted with the recombinant phage displaying 
HBcAg-binding peptide (3). The well is heated up to release the phage 
DNA (4). The presence of HBcAg is then confirmed by qPCR of the 
recombinant phage DNA (5).
DIAGNOSIS
Past,  ➣ Traditional methods such as agar gel diffusion 
(Ouchterlony), TEM and radioimmunoassay (RIA) 
were used.  
Present,  ➣ ELISA is used for detecting HBV antigens and antibodies. 
 ➣ PCR and qPCR are employed for detecting HBV DNA.
Future,  ➣ Produce HBV antigens and antibodies using phage 
display technology. 
 ➣ Point-of-care diagnostic methods can be linked to a 
mobile device for detecting HBV serological markers 
and nucleic acids. 
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DRUG DISCOVERY
The worldwide mass vaccination programme on infants has greatly 
reduced incidents of chronic infection and liver cancer. However, 
mutations of the viral genome have lowered the efficiency of the 
current HBV vaccines. Currently, there are approximately 370 
million chronic HBV carriers waiting to be cured. Nucleotide and 
nucleoside analogues have been used to treat chronic HBV infection, 
which suppress the virus replication. Prolonged administration of 
nucleotide and nucleoside analogues have however given rise to 
mutants that are resistant to these anti-viral drugs. Moreover, HBV 
and HIV co-infection further complicates the situation. Treatments 
for these co-infections have further hastened the selection of 
resistant mutants, lowering the effectiveness of anti-viral drugs. 
All of the above evidence has led us to believe in the need for 
continuing development of new therapeutic agents in the effort to 
combat HBV, particularly the newly emerging mutants.
 Traditionally, drugs and therapeutic agents were discovered 
through application of crude extracts from sources such as plants 
and fungi, followed by isolation of active ingredients contributing 
to the desired effects. In modern drug discovery however, structural 
bioinformatics allow in silico screening for chemical compounds 
which interact with a targeted compound, be it a protein, nucleic 
acid, carbohydrate or lipid, with a computer linked to virtual 
chemical libraries. In practice, however, in silico selected 
compounds often end with disappointment due to poor solubility, 
affinity and specificity. 
 Phage-displayed peptide libraries have been employed widely 
for the selection of antiviral peptides against many viruses over the 
last 20 years (see review in Castel et al., 2011). Viral proteins which 
play major roles in HBV replications, such as, the HBsAg, HBcAg 
and DNA polymerase are potential targets for drug discovery. As in 
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most other viruses, the binding of specific ligands toward key players 
of the HBV life cycle would interfere with the virus replication, 
either extracellularly or intracellularly. Extracellularly, peptides or 
antibodies which bind specifically to the virus or the viral-host cell 
receptor can potentially neutralize the infectious virion. Multiple 
groups of researchers have isolated the Fab fragments of antibodies 
by panning phage-displayed Fab fragment libraries against HBsAg, 
and successfully demonstrated their capabilities in neutralizing 
infectious HBV particles (Bose et al., 2005, Jia et al., 2008, Kim 
et al., 2002, Park et al., 2005, Tiwari et al., 2009, Yang et al., 2007, 
Zhang et al., 2004, Zhang et al., 2006). Another popular target for 
panning with phage display peptide libraries, in the effort to discover 
novel anti-viral drugs, is the PreS1 region, due to its important roles 
in both viral assembly and infectivity (Deng et al., 2005a, Deng et 
al., 2005b, Deng et al., 2007, Tan et al., 2005, Wang et al., 2011). 
As for intracellular inhibition, HBcAg is a common target in the 
discovery of HBV inhibitors, due to its role in forming the viral 
nucleocapsid as well as its interactions with the PreS region during 
the viral assembly (Dyson and Murray, 1995, Ho et al., 2003). 
Conversely, extracellular inhibition of the viral cycle is relatively 
straightforward and less complicated, where penetration of the 
inhibitors across the membrane of liver cells is irrelevant, unlike 
the intracellular inhibitors.
Intracellular Targeting 
HBcAg is a vital component of HBV. It assembles into nucleocapsids 
by encapsidating the viral pre-genomic RNA (pgRNA) in the host 
cytoplasm (Bruss, 2004). Through reverse transcriptase, the pgRNA 
is reverse transcribed into partially double stranded genomic DNA 
within the core particle. The HBcAg then interacts with HBsAg 
embedded in the membrane of the endoplasmic reticulum (ER), 
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thereby providing the virus with its envelope needed for infection. 
This matured HBV can then be released from the host through 
secretion via Golgi apparatus. However, not all nucleocapsids 
are secreted out of the host cell. Some of the nucleocapsids are 
recycled back into the nucleus, followed by disassembly of these 
nucleocapsids, thereby unleashing the viral DNA (Kann et al., 2007, 
Rabe et al., 2003).  Therefore, many of the intracellular inhibitors 
are centered around the disruption of HBcAg’s interactions among 
themselves or with the HBsAg. The replication cycle of HBV with 
potential choke points for intracellular inhibitors is illustrated in 
Figure 12.
 HBcAg also functions as a transcriptional activator, where its 
presence contributes to a high level of viral replication (Nassal, 
1999). Hence, anti-viral agents have been designed to target 
HBcAg, including single-chain variable fragment intrabodies 
(Yamamoto et al., 1999), aptamers (Butz et al., 2001) and 
heteroaryldihydropyrimidines (Deres et al., 2003). Through phage 
display technology, intrabody Fab fragments capable of neutralizing 
HBcAg within liver cells were isolated from phage display antibody 
libraries (Serruys et al., 2009, Serruys et al., 2010, Tan et al., 2007, 
Walsh et al., 2011). Further, peptides which inhibit interaction of 
HBcAg with HBsAg were also selected from phage display peptide 
libraries (Dyson and Murray, 1995, Ho et al., 2003).
 HBV was the first virus used in the selection of peptide 
inhibitors from a 6-mer linear phage display peptide library (Dyson 
and Murray, 1995). In this study, a phage displaying peptide, 
LLGRMK, was selected through panning against immobilized 
HBcAg particles. The affinity between the recombinant phage and 
HBcAg was measured, with a K
D
 of 0.17 µM. The corresponding 
synthetic peptide, with the sequence ALLGRMKG, was shown to 
inhibit the association of HBV nucleocapsid and L-HBsAg in vitro 
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(Figure 13). Through transfection of cell culture with replication-
competent HBV plasmid, Böttcher et al. (1998) demonstrated 
the ability of the synthetic peptide ALLGRMKG to reduce HBV 
replication significantly, and that the peptide binding site was 
located at the tips of the spikes formed by amino acids 78-82 
(78DPASR82) of HBcAg. Mutations of the acidic amino acid 
of HBcAg (E77 or D78) to alanine greatly reduced the binding 
affinity of the peptide to the mutated HBcAg (Böttcher et al., 
1998). Eventually, it was proven  by Tang et al. (2007) that these 
residues are essential for the peptide-HBcAg interaction, through 
a cross-linking study. Cryo-electron microscopy was performed to 
solve the 3-dimensional structure of the HBcAg-peptide complex 
but due to insufficient resolution, the detailed binding mechanism 
remained inconclusive (Böttcher et al., 1998).
Figure 12   The replication cycle of HBV. 
The viral replication can be disrupted through intracellular inhibitors 
which prevent capsid assembly or interaction of the nucleocapsids with 
HBsAg.
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Figure 13  Peptide ALLGRMKG inhibits interaction of HBcAg with 
L-HBsAg.
 A peptide with the sequence LLGRMK, that interacts with HBcAg, 
was selected from a phage displayed peptide library.  A synthetic 
peptide with the sequence ALLGRMKG (A & G at both ends of the 
peptide are from the gpIII protein of the fusion phage) inhibits the 
association of HBcAg particles with L-HBsAg containing PreS1, PreS2 
and S regions.
 In 2003, two cyclic peptides, CWSFFSNIC and CWPFWGPWC, 
were isolated through biopanning with a disulfide-constrained phage 
displayed peptide library against HBcAg. These cyclic peptides 
bind HBcAg with more than 10-fold higher strength compared to 
the linear peptide LLGRMK. The corresponding cyclic peptides 
synthesized chemically were shown to inhibit the association of 
HBcAg and L-HBsAg. It also blocked the binding of C1-5, a 
monoclonal antibody which binds HBcAg at amino acids 78-83 
(Ho et al., 2003). The interactions between the cyclic peptides and 
HBcAg are believed to be hydrophobic, as both the conformational 
constraint cyclic peptides and the immunodominant region of 
HBcAg are mainly composed of hydrophobic amino acids. Due 
to the hydrophobicity of these cyclic peptides, the 3-dimensional 
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structures of the cyclic peptides in complex with HBcAg have not 
been solved. Thus, further modifications on the peptides are required 
to improve their solubility.   
Extracellular Targeting
For an infectious HBV to replicate, the first step involves its 
interaction with the host cell receptor, followed by integration of 
the nucleocapsid into the cell. Hence, molecules which mimic the 
structure of these receptors can potentially bind to HBV, preventing 
further interaction of the virion with the hepatocyte, thereby halting 
the infection.  The study of HBV infection remains challenging 
until today, due to its narrow host range as well as the absence of 
a cell line suitable for HBV infection and propagation (Beck and 
Nassal, 2007). Thus, most of our understanding regarding HBV 
infection comes from studies on duck HBV (DHBV) which revealed 
several glycoproteins as potential receptors for DHBV, such as the 
gp180/p170 and GST-PreS polypeptides (Schultz et al., 2004). 
These glycoproteins have been classified as prototype members 
of the membrane bound carboxypeptidase D (CPD) (Kuroki et 
al., 1995, Tong et al., 1995). Urban et al. (1999) showed that the 
PreS region of DHBV binds to duck CPD with a K
D
 of 0.46 nM, 
and that they play vital roles in the virus attachment and entry via 
carboxypeptidase-like (A and B domains) and non-enzymatic (C 
domain) domains, respectively (Urban et al., 2000). Even with the 
DHBV host receptors identified, no promising inhibitor has been 
reported so far.
 On the other hand, the PreS1 region of HBV has been in the 
spotlight for anti-viral studies through phage display technology, 
due to its function in viral assembly and infectivity (Deng et al., 
2007, Tan et al., 2005, Wang et al., 2011). A cyclic peptide, with 
the sequence CETGAKPHC, was selected through panning of 
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disulfide-constrained phage display peptide library against the 
plasma purified HBsAg (subtype ad).  We have demonstrated that 
CETGAKPHC binds to the immunodominant region of HBsAg 
(amino acids 111-156) with K
D
 of 2.9 ± 0.9 nM and 0.83 ± 0.63 
nM, respectively (Tan et al., 2005). Years later, through a nuclear 
magnetic resonance (NMR) study, Muhamad et al. (2013) revealed 
that this peptide in fact adopts cis/trans conformations due to 
isomerization of the proline residue.  In addition, in silico analysis 
has also revealed two binding sites that correspond to the first 
(amino acids 107-137) and second (amino acids 138-149) loops of 
the immunodominant region of HBsAg (Muhamad et al., 2013). 
As blocking of HBsAg can potentially neutralize the infectivity of 
HBV, this peptide can be further developed into a therapeutic agent 
targeting the extracellular virion.
 Instead of using the plasma purified HBsAg, Deng et al. (2007) 
used thioredoxin-PreS fusion protein as a bait to isolate peptides 
which interact with the PreS regions of HBsAg from a phage display 
cyclic peptide library. In this experiment, thioredoxin-PreS fusion 
protein was used, due to its high solubility and stability over the 
PreS region expressed alone (Deng et al., 2005a). The isolated 
peptides have a common sequence motif of WTXWW (X, flexible), 
and were demonstrated to interact with the PreS1 region at amino 
acids 21 to 47 (PreS1
21-47
). Mutational analyses were performed 
on these PreS1 binding peptides. It was found that the mutation of 
tryptophan to alanine but not phenylalanine abolished the binding 
of the peptides to the PreS1, leading the authors to speculate that the 
tryptophan/phenylalanine, due to their amphipathic characteristics, 
may mediate interaction of protein and lipid/aqueous interfaces 
during the viral attachment (Deng et al., 2007). A homology search 
and subsequent analysis have revealed a lipoprotein lipase (LPL), a 
key enzyme involved in lipoprotein metabolism, containing amino 
acid sequence SWSDDWWS at its C-terminal region, as a potential 
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HBV receptor, where the interactions between LPL with PreS1
21-47 
and HBV particles have been demonstrated through in vitro binding, 
virus capture and cell attachment assays (Deng et al. 2007). Apart 
from the findings of Deng et al. (2007), several other potential HBV 
receptors on HepG2 cells were also reported to have interacted with 
PreS1
21-47 
(Dash et al., 1992, De Falco et al., 2001). These PreS1 
binding peptides which mimic the binding site of potential HBV 
receptors can be exploited to reduce viral infectivity by blocking 
the viral attachment to a hepatocyte.  
 Deng et al. (2005b) and Wang et al. (2011), respectively, 
isolated a cyclic peptide (CSRLLYGWC) and a linear peptide 
(KHMHWHPPALNT) from phage display peptide libraries selected 
against the PreS1. However, there was no consensus sequence 
observed between these peptides and those isolated by Tan et al. 
(2005) and Deng et al. (2007).  This observation suggests that with 
different phage libraries and selection methods, different peptides 
targeting different parts of HBV may be discovered. On the other 
hand, the diversity of the selected peptide sequences indicates that 
various cellular proteins are involved during the viral attachment. 
Therefore, targeting these proteins, be it viral proteins or host cell 
receptors, could one day reduce the viral infectivity in humans.
DRUG DISCOVERY
Past,  ➣ Corticosteroids and immunosuppressive drugs were 
used to treat chronic hepatitis B.
Present,  ➣ Interferon-α and nucleoside analogues are used to 
treat chronic hepatitis B.
Future,  ➣ Combination therapy with drugs targeting the HBV 
replication cycle. These drugs are delivered specifically 
to liver cells.
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DRUG AND GENE DELIVERY
Most liver cancer cases are caused by prolonged HBV infection. 
Liver cancer is the world’s fifth most common cancer, accounting 
for 5.6% of all human cancers and ranks third among cancer-related 
mortalities (Thomas et al., 2010). In recent years, gene therapy has 
gained popularity amongst researchers working on an effective 
treatment for cancer, and virus-based nanoparticles, particularly 
bacteriophages, have been proposed as gene and drug delivery 
vectors. The use of phages comes with many advantages. Their 
coat proteins provide additional protection for drugs and genetic 
materials packaged within the particles, keeping the cargo intact 
for an extended period of time. Apart from being physically stable 
in a wide range of pH and temperatures (Jepson and March, 2004), 
the phage propagation can easily be scaled up with a relatively low 
budget. As bacteriophages lack tropism for eukaryotic cells, they 
are generally safe to be used as vessels for gene and drug delivery. 
 
Bacteriophages as Drug and Gene Delivery Vectors  
The specif ic targeting and internalization of recombinant 
bacteriophage displaying integrin-binding peptides into mammalian 
cells were demonstrated by Hart et al. (1994). In another independent 
study performed by Yokohama-Kobayashi and Kato (1994), the 
transfer of genetic materials into a mammalian cell was successfully 
performed through bacteriophage in the presence of DEAE dextran 
and lipopolyamine. Five years later, Larocca et al. (1999) delivered 
a reporter gene encoding the green fluorescent protein (GFP) into 
a mammalian cell, through the use of recombinant M13 phage 
displaying fibroblast growth factor on its surface. 
 HBV infection is believed to be initiated by interaction of its 
envelope protein, particularly the PreS regions of HBsAg, with a 
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specific host receptor located on the surface of the liver cell. In order 
to develop a gene delivery system, the PreS regions were fused 
to the pIII protein of phage M13 (Kok et al., 2002) and used for 
transfection of HepG2, a human hepatocarcinoma cell line (Tang, 
2008). Although the recombinant phage M13-PreS was shown to 
transfect HepG2 cells, the efficiency was well below expectations, 
probably due to the low copy number of pIII (5 per phage).  To 
increase transfection efficiency, Tang et al. (2009) divided the 
PreS1 region into 2 shorter fragments, residues 1-47 and 60-108. 
These fragments were fused separately to the 10B protein of phage 
T7, in which 415 copies of fragments per phage were displayed. In 
comparison, the recombinant phage displaying amino acids 60-108 
was shown to be the most effective in transfecting and internalizing 
into HepG2 cells, in a time- and dose-dependent manner (Tang et 
al., 2009).
 Phage delivery based on the PreS regions targets both normal 
and cancerous liver cells. Thus, the cargo should not contain any 
materials harmful to normal liver cells. For delivery of anti-tumor 
drugs such as doxorubixin, which is cytotoxic towards both normal 
and cancerous cells, a more specific navigating ligand is required. 
Therefore, Zhang et al. (2007) selected a ligand that specifically 
targets the cancerous liver cell through panning of the phage-peptide 
library against HepG2 and subtraction with L-02 (normal) cell lines. 
Through an in vivo study with BALB/c mice, they demonstrated that 
the recombinant phage displaying the ligand FQHPSFI bound to 
tumor cells following an intravenous injection. This further confirms 
the potential of phage display in drug or gene delivery systems to 
target hepatocellular carcinoma (HCC).  However, before a phage 
can be applied in humans, the specificity of the phage towards 
human microflora must be studied in depth, to avoid changes of 
microbiome patterns in a healthy individual.
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Virus-like Particles as Drug and Gene Delivery 
Vectors
Similar to phage particles, recombinant virus-like particles such 
as the HBV capsid can also be used for targeted delivery of drugs 
and genes. The HBV capsid contains 180 or 240 copies of HBcAg, 
which form small and large icosahedral structures with triangulation 
number of T=3 and T=4, respectively (Crowther et al., 1994).
 The HBV capsid has been studied thoroughly as a molecular 
carrier for foreign epitopes in the development of multivalent 
vaccines, over the past 30 years (for reviews, see Murray and Shiau, 
1999, Pumpens and Grens, 2001, Whitacre et al., 2009). In addition 
to its popular use in vaccine development, Lee and Tan (2008) 
demonstrated that the HBV capsid can dissociate into HBcAg 
dimers in the presence of urea, and the dimers re-associate back 
into capsid upon the removal of denaturants through dialysis. By 
exploiting this feature, Lee and Tan (2008) successfully packaged 
GFP within the inner cavity of the HBV capsid, thereby opening the 
window of opportunity for its further development into a targeted 
nanoparticle delivery system. 
 Via dissociation and re-association of the HBV capsid, Lee et 
al. (2012) packaged fluorescein labelled oligonucleotides within 
the HBV capsid. HBV capsids are spiky, where each of the spikes 
is formed from a bundle of four α-helical polypeptides of HBcAg 
dimer, two from each monomer. As mentioned earlier, the ligand 
LLGRMK was isolated from a phage displayed peptide library 
panned against the HBV capsid (Dyson and Murray, 1995). Cryo-
electron microscopy (Böttcher et al., 1998) and mass-spectrometry 
(Tang et al., 2007) revealed that the binding site for this ligand to 
the HBV capsid is located precisely at the tip of the spike. Based 
on these findings, Lee et al. (2012) designed a 24-mer peptide 
comprising cell-internalizing peptides (CIP) at the N-terminus 
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and LLGRMK at the C-terminus, in which LLGRMK served as 
a ‘nano-glue’ that directed and connected the CIP to the tip of the 
HBV capsid’s spike (Figure 14). The glued CIP-capsid complex 
carrying fluorescein labelled oligonucleotides was then cross-
linked chemically to strengthen the structure through formation 
of covalent bonds. This complex was then used to transfect HeLa 
cells, where fluorescence signals within the cells were detected, 
indicating successful delivery of the oligonucleotides (Figure 15). 
Therefore, a combination of phage display, virus-like particles and 
the nano-glue concept can create innovative applications, not only 
to combat HBV, but other diseases as well.
Figure 14  Display of cell-internalizing peptide (CIP) via the nano-glue.
The nano-glue with the sequence LLGRMK is used to display cell- 
internalizing peptide (CIP) on the surface of the HBV capsid.  The 
CIP is synthesized at the N-terminus of the nano-glue which interacts 
specifically with the HBcAg dimer. The Lys in the nano-glue is cross-
linked to Asp or Glu, located at the tip of the HBcAg dimer.
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Figure 15  Delivery of fluorescent oligonucleotides into HeLa cells.
HBV capsid is dissociated into dimer by using urea. Oligonucleotides 
labelled with fluorescence are added and the urea is removed by 
dialysis.  The HBcAg self-assembles to package the oligonucleotides.  
CIP-nano-glue is cross-linked to the capsid packaged with the 
oligonucleotides and then added to HeLa cells.
DRUG AND GENE DELIVERY
Past &
Present,
 ➣ Drugs are distributed throughout the body in traditional 
and conventional drug delivery systems.
Future,  ➣ Specific drug delivery to the liver or specific organs by 
means of  nanomedicine which employs nanoparticles.
 ➣ The loaded drugs can inhibit viral replication and kill 
cancer cells simultaneously.
CONCLUSION
Recombinant	HBV	vaccine	produced	in	yeast	has	saved	countless	
lives	worldwide.	 	However,	 the	 emergence	 of	 vaccine	 escape	
mutants	and	a	dramatic	increase	in	the	population	co-infected	with	
HBV	and	HIV		strongly	justify	the	need	for	a	better	HBV	vaccine.	
Virus-like	 particles	 are	 good	 options	 for	 scientists	 to	 invent	 a	
vaccine	against	HBV	and	HIV	infections.	
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	 ELISA	involving	antibodies	is	widely	used	for	the	detection	of	
HBV	serological	markers.	However,	production	of	antibodies	with	
animals	 or	 hybridoma	 technology	 is	 laborious,	 time	 consuming	
and	 costly.	These	 limitations	 can	 be	 overcome	 by	 displaying	
peptides	and	antibodies	on	phage	particles	as	diagnostic	reagents	
for	detecting	HBV	serological	markers.	Our	 research	group	has	
demonstrated	that	phage-ELISA	can	be	combined	with	qPCR	for	
the	detection	of	HBV	antigens.		In	this	digital	age,	point-of-care	
diagnostic	methods	can	be	linked	to	a	mobile	device	for	detecting	
HBV	serological	markers	and	the	viral	nucleic	acids.	
	 Currently,	 there	 is	 no	 effective	 cure	 for	HBV	 infection.	
Interferon-a	is	commonly	used	to	treat	chronic	hepatitis	B	patients	
but	the	success	rate	is	less	than	50%.		Treatment	of	chronic	hepatitis	
B	carriers	with	nucleoside	analogues	has	resulted	in	the	selection	of	
drug	resistant	mutants.	Multiple	drug	therapy	holds	the	best	hope	
to	clear	the	virus	in	chronic	patients.		In	order	to	search	for	new	
therapeutics,	phage	displayed	peptide	libraries	were	used	to	select	
ligands	that	inhibit	the	intracellular	and	extracellular	steps	of	the	
HBV	life	cycle.	These	ligands	are	lead	compounds	and	will	certainly	
occupy	 the	 experiments	 of	many	 scientists	who	 are	 developing	
potent	anti-HBV	drugs.
 In conventional drug delivery systems, anti-viral drugs are 
distributed throughout the body which causes side effects in normal 
cells. Thus, there is an urgent need to develop a specific drug 
delivery system to target anti-HBV drugs to the liver.  The delivery 
vehicle must be stable under physiological conditions and the cargo 
released when the vehicle is close to the liver cells or taken up 
by the cells.  In this light, HBcAg VLP is an excellent packaging 
material for therapeutic drugs. These drugs can be targeted to a 
specific organ or a tissue by displaying a CIP on the VLP via the 
nano-glue concept. However, the stability and pharmacological 
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activity of the nano-vehicle and its therapeutic drugs must first be 
studied thoroughly. 
 The entire world is now facing scary HBV threats with the 
emergence of vaccine escape and drug resistant mutants, as well 
as co-infection with HIV.  The weapons currently being used to 
fight this deadly virus are losing their efficiency.  Thus, they have 
to be sharpened immediately.  New heroes and innovative ideas are 
desperately needed to continue this incomplete battle.
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Figure 16  Wen Siang and Ken Murray.
The photo was taken in December 2005, when Wen Siang was in 
Edinburgh learning crystallography and NMR spectroscopy.
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